Article

Scorecard on Medicare Payment Reform

An independent review of Medicare payments reveals that 42% of the healthcare dollars Medicare paid to providers in its fee-for-service program in 2013 were designed to boost the value of care patients receive.

An independent review of Medicare payments reveals that 42% of the healthcare dollars Medicare paid to providers in its fee-for-service program in 2013 were designed to boost the value of care patients receive. Catalyst for Payment Reform (CPR), a nonprofit coalition of employers and other healthcare purchasers pushing for better value in healthcare, released the findings today in its Scorecard on Medicare Payment Reform, the first such analysis of the billions of dollars Medicare pays to healthcare providers.

CPR’s Scorecard comes on the heels of an announcement by HHS that it has set ambitious goals for increasing the proportion of Medicare payments designed to improve the value of care patients receive. HHS goals include tying 50% of traditional, or fee-for-service, Medicare payments to quality or value by the end of 2018 through alternative payment models. CPR’s groundbreaking review of Medicare payments will provide a baseline against which to track value-oriented Medicare payments going forward.

Read the press release: http://bit.ly/1KeHdpQ

Related Videos
Jaime Almandoz, MD, MBA
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
Galen Shearn-Nance, BS
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Dr Johnie Rose
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Leigh Maria Ramos-Platt, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo